v3.26.1
Summary of Significant Accounting Policies (Details) - USD ($)
 9 Months Ended 12 Months Ended
Mar. 31, 2023
Feb. 28, 2026
Feb. 28, 2025
Dec. 31, 2025
May 31, 2025
Dec. 31, 2024
May 31, 2024
Dec. 31, 2023
Summary of Significant Accounting Policies [Line Items]                
Allowance for credit losses               $ 521,007
Allowance for credit losses           522,191
Estimated useful life       5 years        
Lease term       12 months        
Written-down of inventories           13,206
Vesting period term 6 months              
Management approach to determine reportable segments description       The Group operates and manages its business as a single operating and reportable segment. The Group’s CODM has been identified as the Chief Executive Officer who reviews the consolidated net income (loss) when making decisions about allocating resources and assessing performance of the Group.        
Executive Chairman       Chief Executive Officer        
Other revenue           431,378
Revenue from the agreements   $ 107,400            
Related Parties [Member]                
Summary of Significant Accounting Policies [Line Items]                
Allowance for credit losses       522,191   522,191    
Government Subsidies [Member]                
Summary of Significant Accounting Policies [Line Items]                
Written-down of inventories         $ 0.9  
DiamiR Biosciences Corp. [Member]                
Summary of Significant Accounting Policies [Line Items]                
Management approach to determine reportable segments description         The Company performs research and development activities of its own and for others substantially in one location using resources common to internal research activities and revenue-producing services, which have been limited to date.      
Executive Chairman         Chief Executive Officer      
Cash equivalents            
FDIC insured limits         250,000      
Impairment charges on long-lived assets            
Other revenue   190,355 $ 631,729   631,729   1,319,531  
Revenue from the agreements   107,400       89,281  
Minimum [Member]                
Summary of Significant Accounting Policies [Line Items]                
Vesting period term       9 months 15 days        
Maximum [Member]                
Summary of Significant Accounting Policies [Line Items]                
Vesting period term       21 months 15 days        
Maximum [Member] | DiamiR Biosciences Corp. [Member]                
Summary of Significant Accounting Policies [Line Items]                
FDIC insured limits   250,000            
Other revenue [Member]                
Summary of Significant Accounting Policies [Line Items]                
Other revenue   60,000 100,000          
Other revenue [Member] | DiamiR Biosciences Corp. [Member]                
Summary of Significant Accounting Policies [Line Items]                
Other revenue   $ 60,000 $ 100,000   100,000      
Unbilled Revenues [Member] | DiamiR Biosciences Corp. [Member]                
Summary of Significant Accounting Policies [Line Items]                
Contract asset           $ 89,281